Your browser doesn't support javascript.
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
Rincon-Arevalo, Hector; Choi, Mira; Stefanski, Ana-Luisa; Halleck, Fabian; Weber, Ulrike; Szelinski, Franziska; Jahrsdörfer, Bernd; Schrezenmeier, Hubert; Ludwig, Carolin; Sattler, Arne; Kotsch, Katja; Potekhin, Alexander; Chen, Yidan; Burmester, Gerd R; Eckardt, Kai-Uwe; Guerra, Gabriela Maria; Durek, Pawel; Heinrich, Frederik; Ferreira-Gomes, Marta; Radbruch, Andreas; Budde, Klemens; Lino, Andreia C; Mashreghi, Mir-Farzin; Schrezenmeier, Eva; Dörner, Thomas.
  • Rincon-Arevalo H; Department of Nephrology and Intensive Medical Care, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Choi M; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Stefanski AL; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Halleck F; Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia.
  • Weber U; Department of Nephrology and Intensive Medical Care, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Szelinski F; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Jahrsdörfer B; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Schrezenmeier H; Department of Nephrology and Intensive Medical Care, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ludwig C; Department of Nephrology and Intensive Medical Care, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sattler A; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kotsch K; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Potekhin A; Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics. German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Chen Y; Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics. German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Burmester GR; Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics. German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Eckardt KU; Department for General and Visceral Surgery, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Guerra GM; Department for General and Visceral Surgery, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Durek P; MVZ Diaverum Neubrandenburg, Neubrandenburg, Germany.
  • Heinrich F; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ferreira-Gomes M; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Radbruch A; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Budde K; Department of Nephrology and Intensive Medical Care, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Lino AC; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Mashreghi MF; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Schrezenmeier E; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
  • Dörner T; Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.
Sci Immunol ; 6(60)2021 06 15.
Article in English | MEDLINE | ID: covidwho-1369380
Semantic information from SemMedBD (by NLM)
1. Humoral Immunity PROCESS_OF Patients
Subject
Humoral Immunity
Predicate
PROCESS_OF
Object
Patients
2. Humoral Immunity PROCESS_OF Kidney Transplant Recipient
Subject
Humoral Immunity
Predicate
PROCESS_OF
Object
Kidney Transplant Recipient
3. Kidney Failure PROCESS_OF Patients
Subject
Kidney Failure
Predicate
PROCESS_OF
Object
Patients
4. Humoral Immunity PROCESS_OF Patients
Subject
Humoral Immunity
Predicate
PROCESS_OF
Object
Patients
5. Humoral Immunity PROCESS_OF Kidney Transplant Recipient
Subject
Humoral Immunity
Predicate
PROCESS_OF
Object
Kidney Transplant Recipient
6. Kidney Failure PROCESS_OF Patients
Subject
Kidney Failure
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
Patients with kidney failure are at increased risk for SARS-CoV-2 infection making effective vaccinations a critical need. It is not known how well mRNA vaccines induce B and plasma cell responses in dialysis patients (DP) or kidney transplant recipients (KTR) compared to healthy controls (HC). We studied humoral and B cell responses of 35 HC, 44 DP and 40 KTR. Markedly impaired anti-BNT162b2 responses were identified among KTR and DP compared to HC. In DP, the response was delayed (3-4 weeks after boost) and reduced with anti-S1 IgG and IgA positivity in 70.5% and 68.2%, respectively. In contrast, KTR did not develop IgG responses except one patient who had a prior unrecognized infection and developed anti-S1 IgG. The majority of antigen-specific B cells (RBD+) were identified in the plasmablast or post-switch memory B cell compartments in HC, whereas RBD+ B cells were enriched among pre-switch and naïve B cells from DP and KTR. The frequency and absolute number of antigen-specific circulating plasmablasts in the cohort correlated with the Ig response, a characteristic not reported for other vaccinations. In conclusion, these data indicated that immunosuppression resulted in impaired protective immunity after mRNA vaccination, including Ig induction with corresponding generation of plasmablasts and memory B cells. Thus, there is an urgent need to improve vaccination protocols in patients after kidney transplantation or on chronic dialysis.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / Immunocompromised Host / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Type of study: Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: SCIIMMUNOL.ABJ1031

Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / Immunocompromised Host / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Type of study: Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: SCIIMMUNOL.ABJ1031